6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Main Article Content

Mark Lebwohl
Icahn School of Medicine at Mount Sinai, New York, NY

Bruce Strober
Yale University School of Medicine, New Haven, CT

Amy Schrader
CorEvitas, LLC, Waltham, MA

Alvin Li
CorEvitas, LLC, Waltham, MA

Thomas Eckmann
CorEvitas, LLC, Waltham, MA

Baojin Zhu
Eli Lilly and Company, Indianapolis, IN

William Malatestinic
Eli Lilly and Company, Indianapolis, IN

Julie Birt
Eli Lilly and Company, Indianapolis, IN

Meghan Feely
Eli Lilly and Company, Indianapolis, IN

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR

Keywords

psoriasis, biologic therapies, real-world

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.232

Article Details

How to Cite
Lebwohl, M., Strober, B., Schrader, A., Li, A., Eckmann, T., Zhu, B., Malatestinic, W., Birt, J., Feely, M., & Blauvelt, A. (2023). 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. SKIN The Journal of Cutaneous Medicine, 7(6), s232. https://doi.org/10.25251/skin.7.supp.232
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>